• All about Allergens
  • 250K HP 2017
  • AAP Epi update 2017
  • AIFA registered charity
  • Information for health professionals
ASCIA News

  • Travel information for people at risk of anaphylaxis
    July 20, 2017:   The recent report of a child having an allergic reaction on a flight who required treatment with adrenaline has highlighted the need for planning ahead when travelling with allergies. The ASCIA travel plan and checklist have been developed to assist passengers at risk of...
  • New National Allergy Strategy free online training for food service
    July 17, 2017:  In response to engagement with key stakeholders in the food service industry, a free online training course that includes videos and interactive activities has been launched today by the National Allergy Strategy, a partnership between Australia’s peak allergy bodies, ASCIA and...
  • ASCIA 2017 registration and abstract submission deadline extended to 28 July 2017
    July 14, 2017:  The ASCIA 2017 Conference abstract submission and early bird registration deadline has been extended until midday AEST on Friday 28 July 2017. Please note that no further deadline extensions will be possible, as we need to allow time to publish abstracts on the ASCIA 2017 APP ...
  • New National Allergy Strategy ‘250K’ website for teens and young adults
    June 26, 2017:  The new National Allergy Strategy youth project’s 250K website was launched today by Minister Gillespie. The 250K website is a hub for the 250,000 young Australians living with severe allergies, developed in response to a national online survey and focus groups sessions wit...
  • National Allergy Strategy funding announcement
    June 26, 2017:  It is a pleasure to advise that the National Allergy Strategy has been successful in receiving $1 million of funding over the next two years from the Australian Government.  This funding will be used to implement a national allergy prevention program. Minister Gillespie p...
  • Bee venom immunotherapy update
    June 14, 2017:   Following the previous communication earlier this year from Stallergenes Greer regarding the shortage of ALBEY honey bee venom 550mcg, the US/Canadian approved 550mcg-concentrated Hymenoptera honey bee venom freeze-dried powder has been authorised for supply under S19A (1), of...
  • 3 second EpiPen®s are now available
    June 13, 2017: EpiPen® and EpiPen®Jr adrenaline (epinephrine) autoinjectors with the 3 second label will start to enter pharmacies in Australia and New Zealand from 13 June 2017 onwards.  The devices have not changed, just the instructions on the label, which now include: Reduced inje...
  • ASCIA 2017 Conference registration and abstract submission now open
    June 1, 2017:  With an outstanding program featuring 8 international speakers and a venue located on the spectacular Waitematā Harbour in Auckland, this conference is sure to be a highlight of the year for ASCIA members and other health professionals with an interest in allergy and clinic...
  • FSANZ adds lupin to mandatory allergen labelling list
    May 31, 2017:  Food Standards Australia New Zealand (FSANZ) has added lupin to the list of 9 allergens that must be declared on food labels, following consideration by ministers responsible for food regulation. Food businesses have 12 months from 25 May 2017 to meet the requirements. The 10 f...
  • Australian peanut allergy treatment receives $10 million in funding
    May 29, 2017:  The development of a promising new treatment for peanut allergy in children will be the first project to receive $10 million in funding under the Turnbull Government’s Biomedical Translation Fund (BTF).  The Minister for Health, Greg Hunt, and the Minister for Industry, In...
  • New ASCIA Guide for health professionals on introduction of peanut to infants with severe eczema and/or food allergy
    May 18, 2017:    A new ASCIA Guide for introduction of peanut to infants with severe eczema and/or food allergy has been developed, to provide options and information for health professionals (particularly GPs) about introducing peanut to infants with severe eczema and/or existi...
  • ASCIA Guidelines - Vaccination of the egg-allergic individual - 2017 update
    May 17, 2017:  A revised version of the ASCIA Guidelines for vaccination of the egg-allergic individual is now available, which aims to provide updated recommendations for vaccination of egg-allergic individuals, consistent with international and current Australian and New Zealand Guidelines. ...
  • Updated ASCIA anaphylaxis resources webpage
    May 15, 2017  ASCIA has recently undertaken a large systemic review of ASCIA patient information (around 90 articles) on the ASCIA website. As a result of this process we have updated the ASCIA anaphylaxis resources webpage, to make it easier to locate and access resources: www.allergy.org.au...
  • Thunderstorm asthma review
    May 3, 2017  Last week a report titled “Review of response to the thunderstorm asthma event of 21–22 November 2016” was released by the Inspector-General for Emergency Management on the Victorian thunderstorm asthma event in November 2016, which is believed to have resulted in nine deaths. ASC...
  • Urgent TGA Medicine Recall – EpiPen 300 batches 5FA665, 5FA6651, 5FA6652, 5FA6653 (expiry April 2017)
    Apr 2, 2017  Further to the news issued on March 20, no additional batches of EpiPen® 300 adrenaline autoinjectors supplied in Australia or New Zealand have been recalled, as the most recent batches recalled were supplied in other countries.  Mar 20, 2017:   Alphapharm Pty Ltd...
ASCIA is a WAO member society

ASCIA is a WAO member society
Follow ASCIA

ASCIA on facebookASCIA on TwitterASCIA on YouTube

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Disclaimer and Privacy

The ASCIA website is intended for use by ASCIA members, other health professionals, the general public and media. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

 

Sponsors and Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites.

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditation

healthdirect
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the
HONcode standard for
trustworthy health
 information.

Verify here.